The U.S. Food and Drug Administration (FDA) has announced the initiation of its planned phase-out of animal testing in the pharmaceutical industry - a decisive step towards non-animal testing methods. While the pharmaceutical sector represents a long-term opportunity for SenzaGen, this development enhances the company's commercial opportunities as a pioneer in innovative, non-animal testing technologies.
The FDA recently confirmed the beginning of its transition away from animal testing in drug development, starting with monoclonal antibodies (mAbs). The decision marks the first tangible step in implementing the Modernization Act 2.0 and signals a clear industry-wide shift towards alternative testing methods.
"This is a significant milestone for the industry as a whole. The FDA's announcement confirms that regulatory authorities are now actively driving the transition to non-animal testing methods - a development that we believe will, over time, strengthen the market potential for our technologies in toxicology and efficacy," says Peter Nählstedt, CEO and President of SenzaGen.
The FDA's decision is the clearest regulatory signal to date that the shift towards non-animal testing is accelerating. This further reinforces SenzaGen's position as a pioneer in innovative testing methods based on machine learning (AI), genomics, and organoids.
Read more: FDA press release
Contacts
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44
About us
SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.
